Su1969 ASSESSING THE RELIABILITY OF CURRENT AI PLATFORMS IN RELAYING HEALTH INFORMATION RELATED TO CROHN'S DISEASE, ULCERATIVE COLITIS, AND COLORECTAL CANCER.
Read More →
Maggio 2024
Risultati per: Lesioni ulcerative dei genitali
Questo è quello che abbiamo trovato per te
Su1909 AN INVESTIGATION INTO THE MICROBIAL COMPOSITION OF PATIENTS WITH ULCERATIVE COLITIS, WITH AND WITHOUT ANXIETY AND DEPRESSION
Read More →
Maggio 2024
Sa1774 SERUM LEUCINE-RICH A 2-GLYCOPROTEIN LEVEL OF LESS THAN 10 MG/ML CAN PREDICT ENDOSCOPIC REMISSION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS.
Read More →
Maggio 2024
Sa1770 PREVALENCE, CAUSES AND IMPACT OF BOWEL URGENCY ON PATIENTS’ QUALITY OF LIFE AND DISABILITY IN ULCERATIVE COLITIS: RESULTS FROM THE B-UNIC COHORT
Read More →
Maggio 2024
Su1734 UPREGULATED TYPE I INTERFERON RESPONSE IS ASSOCIATED WITH ACTIVE INFLAMMATION IN ULCERATIVE COLITIS AND CAUSES INCREASED SUSCEPTIBILITY TO DEXTRAN SULFATE SODIUM-INDUCED COLITIS IN MICE
Read More →
Maggio 2024
Su1732 GUSELKUMAB INDUCTION RESTORES INTESTINAL IMMUNE HOMEOSTASIS AND PROMOTES EPITHELIAL REPAIR IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Read More →
Maggio 2024
Su1728 GUSELKUMAB AND GOLIMUMAB COMBINATION INDUCTION THERAPY IN ULCERATIVE COLITIS RESULTS IN EARLY LOCAL TISSUE HEALING THAT IS SUSTAINED THROUGH GUSELKUMAB MAINTENANCE THERAPY
Read More →
Maggio 2024
Sa2026 LOW-INTENSITY PULSED ULTRASOUND REFLECTS THE STATUS OF MUCOSAL INJURY AND REPAIR THROUGH STAGE-SPECIFIC MIRNAS IN EXPERIMENTAL MODEL OF ULCERATIVE COLITIS
Read More →
Maggio 2024
Su1756 UPADACITINIB IMPROVES CLINICAL AND ENDOSCOPIC OUTCOMES IN ULCERATIVE COLITIS AND CROHN'S DISEASE REGARDLESS OF BASELINE BODY MASS INDEX
Read More →
Maggio 2024
Sa2034 CPA9-HNE: A NEUTROPHIL-SPECIFIC FRAGMENT OF CALPROTECTIN MEASURED IN SERUM CAN MONITOR ENDOSCOPIC AND CLINICAL DISEASE ACTIVITY IN ULCERATIVE COLITIS
Read More →
Maggio 2024
Su1754 COMBINED ORAL MESALAMINE AND BUDESONIDE SUPPOSITORIES YIELD FASTER SYMPTOM RESOLUTION IN ACTIVE ULCERATIVE COLITIS THAN ORAL MESALAMINE MONOTHERAPY. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED ADD-ON STUDY.
Read More →
Maggio 2024
Su1751 ACHIEVEMENT OF CORTICOSTEROID-FREE CLINICAL, ENDOSCOPIC, AND HISTOLOGIC OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH RISANKIZUMAB: RESULTS FROM THE COMMAND STUDY
Read More →
Maggio 2024
Su1748 MUCOSAL IMMUNE CHANGES ASSOCIATED WITH USTEKINUMAB THERAPY IN ULCERATIVE COLITIS
Read More →
Maggio 2024
Su1747 REWIRING OF PATHWAY INTERACTIONS IN INFLAMED TISSUE OF ULCERATIVE COLITIS PATIENTS POINTS TO SPECIFIC LIGANDRECEPTOR ACTIVITIES ON NEUTROPHIL AND MACROPHAGE SUBSETS
Read More →
Maggio 2024
Sa1865 CO-EVOLUTION OF THE FUNGAL AND BACTERIAL MICROBIOME ACROSS DISEASE COURSE IN ULCERATIVE COLITIS
Read More →
Maggio 2024
Su1827 FILGOTINIB IN ULCERATIVE COLITIS: EARLY REAL-WORLD MULTICENTRE UK EXPERIENCE
Read More →
Maggio 2024
